Surviving in the Valley of Death: Opportunities and Challenges in Translating Academic Drug Discoveries

With pharmaceutical companies shrinking their research departments and exiting out of efforts related to unprofitable diseases, society has become increasingly dependent on academic institutions to perform drug discovery and early-stage translational research. Academic drug discovery and translation...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of pharmacology and toxicology 2019-01, Vol.59 (1), p.405-421
Main Authors: Parrish, Marcus C, Tan, Yuan Jin, Grimes, Kevin V, Mochly-Rosen, Daria
Format: Article
Language:English
Subjects:
drug development
drug discovery
translational research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With pharmaceutical companies shrinking their research departments and exiting out of efforts related to unprofitable diseases, society has become increasingly dependent on academic institutions to perform drug discovery and early-stage translational research. Academic drug discovery and translational research programs assist in shepherding promising therapeutic opportunities through the so-called valley of death in the hope that a successful new drug will result in saved lives, improved health, economic growth, and financial return. We have interviewed directors of 16 such academic programs in the United States and found that these programs and the projects therein face numerous challenges in reaching the clinic, including limited funding, lack of know-how, and lack of a regional drug development ecosystem. If these issues can be addressed through novel industry partnerships, the revision of government policies, and expanded programs in translational education, more effective new therapies are more likely to reach patients in need.
ISSN:0362-1642
1545-4304
DOI:10.1146/annurev-pharmtox-010818-021625